Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mirdametinib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Mirdametinib | EXPERIMENTAL | - |
| Mirdametinib and Probenecid | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Mirdametinib | DRUG | Mirdametinib capsules administered orally. |
| Probenecid | DRUG | Probenecid tablets administered orally. |
Inclusion Criteria: 1. Participant has a body mass index greater than or equal to (\>=) 18 and less than or equal to (\<=) 30 kilograms per meter square (kg/m\^²) (inclusive) at Screening. 2. Participant is in good health in the judgement of the investigator on the basis of a medical evaluation per...
Mirdametinib is an investigational small molecule drug being developed by Merck KGaA. It is a MAP2K1 and MAP2K2 inhibitor that is currently in Phase 1 clinical development. Its therapeutic indications have not been disclosed.
Mirdametinib targets MAP2K1 and MAP2K2, also known as MEK1 and MEK2. It is classified as an inhibitor of these kinases. By inhibiting MAP2K1 and MAP2K2, mirdametinib acts on the MAP kinase signaling pathway.
Mirdametinib is being developed by Merck KGaA, which trades under the ticker MKGAF. The company is the sponsor of the clinical program evaluating this investigational small molecule.
Mirdametinib is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The only listed trial is a Phase 1 study, and no completed trials are recorded for this asset.
Mirdametinib is being studied in one active clinical trial, NCT07840612. This Phase 1 study is recruiting and is titled "A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants." It is being conducted in Germany and plans to enroll 17 healthy volunteers.